Adaptive Biotechnologies Sustainability Profile
Adaptive Biotechnologies Corporation, headquartered in the United States, is a pioneering leader in the biotechnology industry, specialising in immune-driven medicine. Founded in 2009, the company has made significant strides in harnessing the power of the adaptive immune system to develop innovative diagnostic and therapeutic solutions. With a focus on areas such as oncology and infectious diseases, Adaptive Biotechnologies offers unique products like the clonoSEQ® assay, which provides precise insights into the immune repertoire. This technology stands out for its ability to detect and quantify specific immune cells, enabling personalised treatment strategies. Recognised for its contributions to precision medicine, Adaptive Biotechnologies has established a strong market position, collaborating with major pharmaceutical companies and research institutions to advance the field of immunology.
DitchCarbon Score
How does Adaptive Biotechnologies's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Adaptive Biotechnologies's score of 25 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Adaptive Biotechnologies's reported carbon emissions
Adaptive Biotechnologies, headquartered in the United States, currently does not report any specific carbon emissions data, as indicated by the absence of figures in kg CO2e. However, the company has made commitments towards climate action, particularly through its participation in the Science Based Targets initiative (SBTi). As of June 2025, Adaptive Biotechnologies is classified as "Committed" to near-term reduction targets, although specific targets or timelines have not been disclosed. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector, which is increasingly focusing on sustainability and reducing environmental impact. While no absolute emissions data is available, Adaptive Biotechnologies' commitment to climate initiatives reflects a growing trend in the industry towards accountability and transparency in carbon management. The absence of emissions data may suggest that the company is in the early stages of its climate strategy or is still developing its reporting framework.
How Carbon Intensive is Adaptive Biotechnologies's Industry?
How Carbon Intensive is Adaptive Biotechnologies's Location?
Adaptive Biotechnologies's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Adaptive Biotechnologies has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
